Research shows that a protein called RNF10 causes fatty liver disease by preventing the liver from burning fat efficiently. In a 2026 study published in the Journal of Clinical Investigation, scientists found that removing RNF10 from mouse livers reduced fat accumulation, inflammation, and scarring. A new treatment that silenced the RNF10 gene in liver cells also successfully reversed liver damage in mice fed an unhealthy diet, suggesting this protein could become a target for future fatty liver disease treatments.
Scientists have discovered that a protein called RNF10 plays a major role in fatty liver disease, a condition where fat builds up in the liver and causes damage. According to Gram Research analysis, when researchers removed or blocked this protein in mice, their livers became healthier with less fat, inflammation, and scarring. The team also tested a new treatment method using special molecules to deliver instructions that shut down RNF10 production directly to liver cells. This approach successfully reduced liver damage in mice fed an unhealthy diet. These findings suggest that targeting RNF10 could become a new way to treat fatty liver disease in humans.
Key Statistics
A 2026 study in the Journal of Clinical Investigation found that hepatic-specific deletion of RNF10 in mice attenuated liver steatosis, inflammation, and fibrosis, while RNF10 overexpression exacerbated metabolic dysfunction-associated steatotic liver disease phenotypes.
Researchers discovered that RNF10 interacts with and degrades CPT1A, a protein essential for fat burning in liver cells, thereby promoting hepatic lipid accumulation and liver inflammation in mice with diet-induced fatty liver disease.
GalNAc-siRNA delivery targeting RNF10 effectively ameliorated diet-induced liver steatosis, inflammation, and fibrosis in mice, demonstrating the therapeutic potential of RNF10 inhibition as a treatment strategy for metabolic dysfunction-associated steatotic liver disease.
The Quick Take
- What they studied: Whether a protein called RNF10 causes fatty liver disease and whether blocking it could treat the condition
- Who participated: Laboratory mice with diet-induced fatty liver disease, plus human tissue samples from patients with the condition
- Key finding: Removing RNF10 from mouse livers reduced fat accumulation, inflammation, and scarring. A new treatment that silenced the RNF10 gene in liver cells also successfully reversed liver damage in mice.
- What it means for you: This research identifies a potential new drug target for fatty liver disease, a condition affecting millions of people worldwide. However, these are early-stage findings in mice, and human trials would be needed before any treatment becomes available.
The Research Details
Researchers conducted multiple experiments using laboratory mice to understand how RNF10 affects the liver. First, they compared RNF10 levels in healthy mice versus mice with fatty liver disease, and also examined human liver tissue samples. They then created mice without the RNF10 gene in their liver cells to see what happened. In another experiment, they added extra RNF10 to mouse livers to see if it made the disease worse. Finally, they tested a new treatment method using special delivery vehicles called GalNAc-siRNA that carry genetic instructions to shut down RNF10 production specifically in liver cells. This last approach mimics how a future medicine might work in humans.
This research approach is important because it moves from observation to cause-and-effect testing. By removing and adding RNF10 separately, scientists could prove that this protein actually causes the disease rather than just appearing alongside it. Testing the new delivery method in mice provides evidence that the treatment could work in living organisms before attempting human trials.
This study was published in the Journal of Clinical Investigation, a highly respected medical research journal. The research used multiple experimental approaches that confirmed each other’s findings, which strengthens confidence in the results. The team tested their findings in both mouse models and human tissue samples. However, because these are laboratory and animal studies, results may not directly translate to humans.
What the Results Show
When researchers deleted the RNF10 gene from mouse liver cells, the mice showed significant improvements in three key areas: they had less fat stored in their livers, reduced inflammation (the body’s harmful immune response), and less liver scarring. In contrast, when researchers added extra RNF10 to mouse livers, the disease got worse, confirming that RNF10 directly causes the problem. The research revealed that RNF10 works by breaking down a protein called CPT1A, which is responsible for burning fat in liver cells. When RNF10 destroys CPT1A, the liver cannot burn fat efficiently, so fat accumulates instead. The most promising finding involved the new treatment approach: when researchers used special delivery molecules to silence the RNF10 gene in mice fed an unhealthy diet, the mice’s livers recovered significantly with reduced fat, inflammation, and scarring.
The study found that RNF10 levels were higher in people with fatty liver disease compared to healthy individuals, suggesting the findings may be relevant to human disease. The researchers identified the specific molecular mechanism by which RNF10 damages the liver, involving a process called ubiquitination, which is how cells mark proteins for destruction. This detailed understanding of the mechanism strengthens the case for developing drugs that target RNF10.
Fatty liver disease has been difficult to treat because scientists didn’t fully understand what causes it. This research adds to growing evidence that specific proteins control whether the liver stores or burns fat. Previous studies identified other proteins involved in liver fat metabolism, but RNF10 appears to be a particularly important control point. The finding that blocking RNF10 helps the liver burn fat more efficiently aligns with other research showing that fat oxidation (burning) is key to preventing liver disease.
This study was conducted entirely in mice and human tissue samples, not in living humans. Mouse livers may respond differently to treatment than human livers. The sample size of human tissue samples was not specified in the research. The study used mice fed an unhealthy diet to model the disease, which may not perfectly match how the disease develops in all humans. Long-term safety and effectiveness of the proposed treatment have not been tested. The delivery method used in mice (GalNAc-siRNA) would need to be adapted and tested in humans before becoming a clinical treatment.
The Bottom Line
Based on this research, RNF10 is a promising target for future fatty liver disease treatments. However, no treatment is currently available. People with fatty liver disease should continue following proven approaches: maintaining a healthy weight, eating a balanced diet low in processed foods and added sugars, exercising regularly, and limiting alcohol. Anyone with fatty liver disease should work with their doctor on an individualized treatment plan. Confidence level: This is early-stage research showing strong promise but requiring further development before clinical use.
This research is most relevant to people with metabolic dysfunction-associated fatty liver disease (MASLD), previously called non-alcoholic fatty liver disease. It may also interest people at risk for the condition, including those who are overweight, have type 2 diabetes, or have metabolic syndrome. Healthcare providers treating liver disease should monitor this research as it develops. People without liver disease do not need to take action based on this study.
If this research leads to a human treatment, it would likely take 5 to 10 years of additional testing before a drug becomes available. Early-stage clinical trials might begin within 2 to 3 years if funding and regulatory approval proceed quickly. People should not expect this treatment to be available soon but can stay informed about clinical trial opportunities.
Frequently Asked Questions
What is RNF10 and why does it cause fatty liver disease?
RNF10 is a protein that breaks down CPT1A, which normally helps the liver burn fat. When RNF10 destroys CPT1A, the liver cannot burn fat efficiently, so fat accumulates instead, causing inflammation and damage.
Can I get a treatment that blocks RNF10 right now?
No, this is early-stage research conducted in mice. Scientists would need to conduct human clinical trials before any RNF10-blocking treatment becomes available, likely taking 5 to 10 years or more.
How does the new GalNAc-siRNA treatment work?
GalNAc-siRNA uses special delivery molecules to carry genetic instructions directly to liver cells, telling them to stop producing RNF10. In mice, this approach successfully reduced liver fat, inflammation, and scarring.
If I have fatty liver disease, what should I do now?
Follow proven approaches: maintain a healthy weight, eat a balanced diet low in processed foods and added sugars, exercise regularly, limit alcohol, and work with your doctor on an individualized treatment plan.
Will this research definitely lead to a new treatment for humans?
This research shows strong promise, but early-stage findings in mice don’t always translate to humans. Additional testing in humans would be needed to confirm safety and effectiveness before any treatment becomes available.
Want to Apply This Research?
- Users with fatty liver disease can track liver health markers through their healthcare provider’s tests: measure ALT and AST enzymes (liver damage indicators) every 3 to 6 months, monitor weight weekly, and record diet quality daily using a food diary feature to identify high-sugar and high-fat foods to reduce.
- Users can set daily goals to reduce processed foods and added sugars, increase physical activity to 150 minutes per week, and track alcohol consumption (limiting to zero if possible). The app can send reminders for these behaviors and celebrate weekly progress toward a healthier weight.
- Create a dashboard showing trends in weight, exercise minutes, and dietary quality over months. Connect with healthcare provider data to display liver enzyme test results when available. Set quarterly check-in reminders to review progress and adjust goals with a healthcare provider.
This article summarizes early-stage research conducted in laboratory mice and human tissue samples. These findings have not been tested in humans and do not constitute medical advice. Fatty liver disease is a serious condition that requires professional medical evaluation and treatment. Anyone with fatty liver disease or concerns about liver health should consult with a qualified healthcare provider before making any changes to their treatment plan. This research identifies a potential future therapeutic target but no treatment based on these findings is currently available for human use. Do not delay seeking medical care based on this information.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.